Nicholas (Nick) J. Sarlis Brief Biosketch – Nov. 2011 Dr. Sarlis is currently Vice President and Head, Med Affairs Dept at Incyte Corp. (Wilmington, DE), responsible for establishing and strategically directing a multi-functional team for the company’s lead program (ruxolitinib; formerly known as: INCB18424), as well as other compounds. He joined Pharma with sanofi-aventis (s-a) US, and reached the Snr. Med. Director level, managing several parts of the s-a Oncology portfolio. Ruxolitinib was appoved for use in the US (TM: Jakafi) on 16 Nov. 2011 for patients with intermediate and high-risk myelofibrosis. Dr. Sarlis currently supports medically all initiatives aiming at the successful commercialization of this brand in the US. Following superb training in Internal Medicine, Molecular Biology, Endocrinology, and Endo. Oncology both in the UK and US, Dr. Sarlis engaged in a decade-long academic career in the US. Dr. Sarlis served sequentially as Snr Clin Investigator at the NIH, and as Assoc Prof at the M. D. Anderson Cancer Center. Through his latter attachment, as an endocrine malignancy KOL himself, he forged lasting relationships with several leading oncologists in N. America, EU & ROW. Over the last 13 years, he has focused on Oncology clinical & translational research.